This study represents the first step on a development path that aims at improving cure rates for advanced hematologic malignancies including ALL, AML and CML-BP by simultaneously targeting different components of the PI3K/Akt/mTOR signaling pathway. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.